S-ICD Sales Exceeding Expectations, Boston Scientific Reports
This article was originally published in The Gray Sheet
Executive Summary
The company said when S-ICD launched that it expected the device to be a major growth driver, and that appears to be working out so far. Boston Scientific now expects the leadless implantable defibrillator to bring in $100 million in revenue this year.
You may also be interested in...
Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales
Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.
Subcutaneous ICD Matches Conventional Defibrillators In Registry
Boston Scientific’s S-ICD subcutaneous implantable cardioverter defibrillator performed well in the EFFORTLESS registry, with clinical event rates and inappropriate shock rates similar to those reported for conventional ICDs in a real-world context.
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”